Recent advances in the production of recombinant subunit vaccines inPichia pastoris

Wang, Man; Jiang, Shuai; Wang, Yefu

doi:10.1080/21655979.2016.1191707

Cited by 83 publications

(64 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This carrier was selected after taking into account two facts: the internal protein is weakly recognized even in mumps-vaccinated individuals [31], and the P. pastoris secreted expression system was already successfully used for the expression of mumps NLPs [30]. This is described as one of the most powerful systems for recombinant protein expression, yielding proteins with high purity [44] and the ability to express viral particles in the form of VLPs [45,46]. Using the same strategy, we successfully expressed, characterized, and purified two mumps NLPs carrying PvCSP sequences that remained stable and presented the appropriate structural conformation, as evidenced by the mean diameter of the particle corresponding to mumps nucleocapsid [30], confirmed after scanning electron microscopy.…”

Section: Discussionmentioning

confidence: 99%

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

et al. 2020

View full text Add to dashboard Cite

Plasmodium vivax is the most common species of human malaria parasite found outside Africa, with high endemicity in Asia, Central and South America, and Oceania. Although Plasmodium falciparum causes the majority of deaths, P. vivax can lead to severe malaria and result in significant morbidity and mortality. The development of a protective vaccine will be a major step toward malaria elimination. Recently, a formulation containing the three allelic variants of the P. vivax circumsporozoite protein (PvCSP—All epitopes) showed partial protection in mice after a challenge with the hybrid Plasmodium berghei (Pb) sporozoite, in which the PbCSP central repeats were replaced by the VK210 PvCSP repeats (Pb/Pv sporozoite). In the present study, the chimeric PvCSP allelic variants (VK210, VK247, and P. vivax-like) were fused with the mumps virus nucleocapsid protein in the absence (NLP-CSPR) or presence of the conserved C-terminal (CT) domain of PvCSP (NLP-CSPCT). To elicit stronger humoral and cellular responses, Pichia pastoris yeast was used to assemble them as nucleocapsid-like particles (NLPs). Mice were immunized with each recombinant protein adjuvanted with Poly (I:C) and presented a high frequency of antigen-specific antibody-secreting cells (ASCs) on days 5 and 30, respectively, in the spleen and bone marrow. Moreover, high IgG titers against all PvCSP variants were detected in the sera. Later, these immunized mice with NLP-CSPCT were challenged with Pb/Pv sporozoites. Sterile protection was observed in 30% of the challenged mice. Therefore, this vaccine formulation use has the potential to be a good candidate for the development of a universal vaccine against P. vivax malaria.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, adjuvants are associated with the onset of local reactions to the vaccination site. Also, the duration the immunity conferred by vaccination is lower, except for live vaccines (78) (Table III).…”

Section: The Development Of a Covid-19 Vaccine: Current Trends And Prmentioning

confidence: 99%

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

et al. 2020

View full text Add to dashboard Cite

In the current context of the pandemic triggered by SARS-cOV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS-cOV-2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a cOVId-19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.

show abstract

“…Recently, subunit vaccines have been replaced with other forms of vaccines. Also, for the production of recombinant subunit vaccines, P. pastoris is more famous than other expression systems (Wang, Jiang, & Wang, 2016). Subunit vaccines often suffer from poor immunogenicity and require certain helper molecules known as adjuvants to induce or enhance an appropriate immune response to the antigen.…”

Section: The Characteristic Features Of P Pastoris Expression Systemmentioning

confidence: 99%

Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins

Keikha

Rezaee

Farsiani

2020

Journal Cellular Physiology

414

220

View full text Add to dashboard Cite

One of the most important branches of genetic engineering is the expression of recombinant proteins using biological expression systems. Nowadays, different expression systems are used for the production of recombinant proteins including bacteria, yeasts, molds, mammals, plants, and insects. Yeast expression systems such as Saccharomyces cerevisiae (S. cerevisiae) and Pichia pastoris (P. pastoris) are more popular. P. pastoris expression system is one of the most popular and standard tools for the production of recombinant protein in molecular biology. Overall, the benefits of protein production by P. pastoris system include appropriate folding (in the endoplasmic reticulum) and secretion (by Kex2 as signal peptidase) of recombinant proteins to the external environment of the cell. Moreover, in the P. pastoris expression system due to its limited production of endogenous secretory proteins, the purification of recombinant protein is easy. It is also considered a unique host for the expression of subunit vaccines which could significantly affect the growing market of medical biotechnology. Although P. pastoris expression systems are impressive and easy to use with well-defined process protocols, some degree of process optimization is required to achieve maximum production of the target proteins. Methanol and sorbitol concentration, Mut forms, temperature and incubation time have to be adjusted to obtain optimal conditions, which might vary among different strains and externally expressed protein. Eventually, optimal conditions for the production of a recombinant protein in P. pastoris expression system differ according to the target protein.

show abstract

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

Cited by 83 publications

References 98 publications

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins

Contact Info

Product

Resources

About